Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Wiener Wachstumsfonds

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 2
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 2
Rounds per year 0.12
Lead investments 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Cosmetics
  • Medical
  • Biotechnology
  • Biopharma
  • Medical Device
Summary

In 2005 was created Wiener Wachstumsfonds, which is appeared as VC. The leading representative office of defined VC is situated in the Vienna. The venture was found in Europe in Austria.

The typical case for the fund is to invest in rounds with 2 participants. Despite the Wiener Wachstumsfonds, startups are often financed by firstVentury Equity, bmp Ventures, PONTIS Venture Partners Management. The meaningful sponsors for the fund in investment in the same round are PONTIS Venture Partners Management, Arax Capital Partners. In the next rounds fund is usually obtained by bmp Ventures, Samsung Electronics, Infineon Technologies.

The important activity for fund was in 2010. The usual things for fund are deals in the range of 1 - 5 millions dollars. The fund is constantly included in less than 2 deals per year.

Among the most popular portfolio startups of the fund, we may highlight TTTech, EUCODIS Bioscience. We can highlight the next thriving fund investment areas, such as Biopharma, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - Austria. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Wiener Wachstumsfonds:
Typical Co-investors
Wiener Wachstumsfonds is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Wiener Wachstumsfonds:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Austria
Funds with similar focus located in Austria:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

EUCODIS Bioscience

Biopharma
Biotechnology
Cosmetics
Medical
Medical Device
$2M17 Mar 2010 Vienna

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Wiener Wachstumsfonds?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 2
Average round size 3M
Rounds per year 0.12
Peak activity year 2007
Lead investments 1
Group Appearance index 0.50

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

EUCODIS Bioscience

Biopharma
Biotechnology
Cosmetics
Medical
Medical Device
$2M17 Mar 2010 Vienna
Crunchbase icon

Content report

The following text will be sent to our editors: